海南海药1月30日公告，预计2025年度营业收入8亿元-9亿元，上年同期营业收入为9.91亿元。预计2025 年度归母净利润亏损3.5亿元-4.3亿元，上年同期亏损15.25亿元。 海南海药1月30日公告，预计2025年度营业收入8亿元-9亿元，上年同期营业收入为9.91亿元。预计2025 年度归母净利润亏损3.5亿元-4.3亿元，上年同期亏损15.25亿元。 ...

格隆汇1月30日｜海南海药公告，预计2025年净亏损3.5亿元—4.3亿元。2025年，在医保、集采等政策环 境影响下，市场竞争加剧，公司创新药尚未上市，新上市仿制药尚未放量，原料药项目陆续转固导致折 旧费用增加，带息负债规模较大导致利息支出较高，进而影响公司业绩。 ...

海南海药公告，预计2025年度净利润为负值。报告期内，公司归属于上市公司股东的净利润预计为亏损 3.5亿元至4.3亿元，亏损额较上年同期有所下降。 ...

证券代码：000566 证券简称：海南海药 公告编号：2026-005 海南海药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 单位：万元 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -43,000 | ～ | -35,000 | -152,520.09 | | 扣除非经常性损益后的净利润 | -48,000 | ～ | -38,000 | -119,465.54 | | 基本每股收益（元/股） | -0.3314 | ～ | -0.2698 | -1.1756 | | 营业收入（如适用） | 80,000 | ～ | 90,000 | 99,070.15 | | 扣除后营业收入（如适用） | 78,000 | ～ | 88,000 | 96,267.22 | 二 ...

证券日报网讯1月27日，海南海药（000566）在互动平台回答投资者提问时表示，截至2026年1月20日公 司股东户数为132189户。 ...

Market Overview - The Shanghai Composite Index fell by 0.64% on January 13, with six industries experiencing gains, led by the oil and petrochemical sector (up 1.62%) and the pharmaceutical and biotechnology sector (up 1.21%) [1] - The defense and military industry and the electronics sector saw the largest declines, down 5.50% and 3.30% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets was 162.743 billion yuan, with only four industries seeing net inflows [1] - The pharmaceutical and biotechnology sector had the highest net inflow of capital at 4.348 billion yuan, followed by the oil and petrochemical sector with a net inflow of 586 million yuan [1] - The electronics industry experienced the largest net outflow, totaling 37.010 billion yuan, followed by the computer industry with a net outflow of 23.107 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector rose by 1.21%, with a total of 478 stocks in the sector, of which 329 stocks increased in value and 16 stocks hit the daily limit [2] - A total of 256 stocks in the sector saw net capital inflows, with 21 stocks receiving over 100 million yuan in net inflows; leading was Mindray Medical with a net inflow of 372 million yuan [2] - The stocks with the highest net outflows included Hainan Haiyao, Huahai Pharmaceutical, and Sanbo Brain Science, with net outflows of 204 million yuan, 164 million yuan, and 153 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - Notable gainers included: - Mindray Medical: up 0.09% with a capital flow of 371.57 million yuan [3] - International Medical: up 9.96% with a capital flow of 290.33 million yuan [3] - Haiwang Biological: up 9.97% with a capital flow of 242.73 million yuan [3] - Boji Pharmaceutical: up 19.96% with a capital flow of 241.23 million yuan [3] - Erkang Pharmaceutical: up 19.95% with a capital flow of 237.43 million yuan [3] Top Losers in Pharmaceutical Sector - Notable losers included: - Hainan Haiyao: down 4.82% with a capital outflow of 203.78 million yuan [5] - Huahai Pharmaceutical: down 3.60% with a capital outflow of 163.67 million yuan [5] - Sanbo Brain Science: down 3.93% with a capital outflow of 153.22 million yuan [5] - Xiangrikui: down 5.49% with a capital outflow of 147.26 million yuan [5] - Luyan Pharmaceutical: down 3.74% with a capital outflow of 110.10 million yuan [5]

格隆汇1月9日丨海南海药（维权）(000566.SZ)公布，股东云南国际信托有限公司－聚利36号单一资金 信托（简称"云南国际信托"）计划在本公告披露之日起15个交易日后的连续90个自然日内以集中竞价交 易方式减持本公司股份不超过12,973,651股，占本公司总股本的1%。 ...

Core Viewpoint - Hainan Haiyao's innovative drug project, Paengabine, has successfully completed Phase IIa clinical trials, showing promising results for treating refractory epilepsy [1] Group 1: Clinical Trial Results - The Phase IIa clinical trial for Paengabine, developed in collaboration with the Shanghai Institute of Materia Medica, has met both primary and secondary clinical endpoints [1] - The drug, a new generation KCNQ potassium channel agonist, is the first of its kind globally and is intended for the treatment of refractory epilepsy [1] - Initial exploratory efficacy indicators suggest that Paengabine can effectively reduce the frequency of seizures in patients with focal epilepsy after 8 weeks of continuous use [1] Group 2: Regulatory and Development Milestones - Paengabine received approval for clinical trials from the National Medical Products Administration and has completed Phase I trials in healthy subjects [1] - The Phase IIa trial was designed as a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Paengabine in patients with focal epilepsy [1] - The trial results indicate that Paengabine has good safety and tolerability profiles, with overall risks being manageable [1]

证券日报网讯 1月9日，海南海药发布公告称，持有海南海药股份有限公司（简称"本公司"）股份68， 295，512股（占本公司总股本比例5.26%）的股东云南国际信托有限公司－聚利36号单一资金信托计划 在本公告披露之日起15个交易日后的连续90个自然日内以集中竞价交易方式减持本公司股份不超过12， 973，651股，占本公司总股本的1%。 （文章来源：证券日报） ...

Core Viewpoint - On January 9, a total of 20 listed companies disclosed plans for share reductions, with no companies announcing share increases on the same day [1][3]. Group 1: Companies Planning to Reduce Shares - Yihua Tong: Shareholder Zhou Zhuqing plans to reduce no more than 0.02% of shares [2]. - Tongda Electric: Shareholders plan to reduce company shares [2]. - *ST Shengxun: Shareholder Liu Mengran and his concerted parties plan to reduce 2.04% and 2.64% of shares respectively [2]. - Hainan Haiyao: Shareholder Yunnan International Trust plans to reduce no more than 1% of shares [2]. - Goldwind Technology: Shareholder Xinjiang Energy plans to reduce no more than 0.2451% of shares [2]. - Haishun New Materials: Shareholders plan to reduce no more than 0.87% of shares [2]. - Kema Technology: Employee strategic placement asset management plan plans to reduce no more than 0.3528% of shares [2]. - Zhongya Co.: Some executives plan to reduce shares [2]. - Baibang Technology: Director Chen Jin plans to reduce no more than 0.14% of shares [2]. - Yaxiang Co.: Shareholder Zhou Junfang plans to reduce no more than 0.22% of shares [2]. - Dingjie Zhizhi: The largest shareholder, Industrial Fulian, has cumulatively reduced 0.66% of shares [2]. - Hehui Optoelectronics: Shanghai Integrated Circuit Fund plans to reduce no more than 2% of shares [2]. - Heyuan Gas: Changjiang Capital has reduced its holdings to below 5% [2]. - Huati Technology: The actual controller plans to reduce no more than 3% of shares [2]. - Qingyuan Co.: A concerted party of the controlling shareholder plans to reduce no more than 0.17% of shares [2]. - Yongxing Co.: Shareholder Chengtou Investment Company plans to reduce no more than 1.042% of shares [2]. - Jiachih Technology: Shareholder Wen Congyingxi plans to reduce no more than 2.5% of shares [2]. - Western Gold: The third largest shareholder, Jinyuan Company, plans to reduce no more than 1% of shares [2]. - Meirui Mining: Shareholder Li Jian plans to reduce no more than 1% of shares [2]. - Jiankai Technology: Shareholder Wu Kaiti plans to reduce no more than 3% of shares [2].